User
Favorite list
As a global market leader with numerous subsidiaries and distributors, Miltenyi Biotec is committed to providing our customers around the world with the highest quality products. In addition to direct selling in more than 20 countries in North America, Europe and Asia/Pacific, Miltenyi Biotec also provides support for our customers through an extensive distributor network covering dozens of additional countries.
While HSCT is a well-founded therapeutic option for the treatment of a variety of hematologic malignancies and non-malignant diseases, it is also associated with severe side effects. The CliniMACS® Cell Separation System offers a variety of tools that enables the removal of T cells, T cells subsets, B cells, and other unwanted cells from hematopoietic stem cell grafts to overcome relapse and side effects like graft-versus-host disease. Different clinical strategies are being evaluated to engineer stem cell grafts for different purposes based on Miltenyi Biotec's cell separation technologies and clinical grade antibodies for different epitopes.
For complete regulatory notices click here.
Copyright © 2020 Miltenyi Biotec and/or its affiliates. All rights reserved.
